CClinicalTrials.gg
Status unknownNCT04705285EFFECTUpdated Jan 12, 2021

Erb:Yag Laser Versus Pelvic Floor Training for the Treatment of Women With Mild to Moderate Stress Urinary Incontinence

An interventional study of Erbium Yag Laser and Pelvic Floor Training in Stress Urinary Incontinence, sponsored by Pontificia Universidad Catolica de Chile. Status unknown at 1 site in Chile. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-12.

Sponsored by Pontificia Universidad Catolica de Chile · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jan 2021), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 1 year 2 months after the study started (first participant enrolled May 2019, registered Aug 2020).
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

This is a pilot study to assess the feasibility and safety to run a randomized controlled trial that compared the effectivity of erbium:yag vaginal laser versus pelvic floor training in women with mild to moderate stress urinary incontinence.

Read the detailed description

This pilot study attempts to demonstrated the feasibility and security to run a randomized controlled study that compared the effectivity of erbium:yag laser used vaginally versus pelvic floor training, coached by a physiotherapist expert in pelvic floor disorders.

Patients are going to be randomized to pelvic floor exercises (10 sessions) or erbium:yag laser (2 sessions), and assess the results at 6 and 12 moths later on.

02

Conditions studied

03

In context

Urinary Incontinence

1,363 studies on the registry are indexed under Urinary Incontinence; 228 are open to participants now.

This study's planned enrollment of 60 is close to the median of 66 across 1,011 interventional studies indexed under Urinary Incontinence.

Browse Urinary Incontinence studies →

Lead sponsor

Pontificia Universidad Catolica de Chile is the lead sponsor of 215 studies on the registry; 56 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • Mild to Moderated Stress Urinary Incontinence

Exclusion criteria

Exclusion Criteria:

  • Mixed Urinary incontinence
  • Pelvic organ prolase greater than stage 2
  • Previous surgery for stress urinary incontinence and/or pelvic organ prolapse
  • Severe Stress urinary incontinence
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Erbium:Yag Laser

    Patients allocated to the erbium:yag laser are going to undergo 2 sessions of vaginal laser, separated by one month each other.

    Device: Erbium Yag Laser

  • Active comparator
    Pelvic floor training

    Patients allocated to pelvic floor training, are goin to undergo 10 sessions of pelvic floor exercises coached by an expert physiotherapist.

    Behavioral: Pelvic Floor Training

Interventions

  • DeviceErbium Yag Laser

    Subjets in the laser arm will undergo 2 sessions of vaginal erbium-yag laser, separated by a month

  • BehavioralPelvic Floor Training

    Patients allocated to pelvic floor training, are goin to undergo 10 sessions of pelvic floor exercises coached by an expert physiotherapist

06

What researchers measure

Primary outcomes

  1. Change in quality of life

    In order to measure quality of life, we are going to use the International Consultation on Incontinence Questionnaire Short Form (ICQI-SF), validate to spanish and in Chile. A higher score in this scale means a worse outcome for the patient.

    Time frame: The questionnaire will be applied at baseline, 6 month and 1 year

Secondary outcomes

  1. Pad test

    A 24 h Pad test will be applied. The pad will be weighted after 24 h of use and the difference between the dry pad and the wet pad is going to be recorded. A great difference means a worse outcome for the patient.

    Time frame: at baseline, 6 month and 1 year

07

Study locations

1 of 1 sites recruiting
  • Hospital Clinico de La Florida
    Santiago, Chile
    • Sebastian Viguera, MD · Contact · sebastian.viguera@gmail.com · +56993316816
    • Victor Miranda, MD · Principal investigator
    • Sebastian Viguera, MD · Sub investigator
    • Sarita Donoso · Sub investigator
    • Gloria Alonso · Sub investigator
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 12, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04705285
Lead sponsor
Pontificia Universidad Catolica de Chile
Responsible party
Sponsor
First posted
Jan 12, 2021
Start date
May 15, 2019
Primary completion
Jun 21, 2021 (estimated)
Completion
Sep 15, 2021 (estimated)
Last update
Jan 12, 2021

Study contacts

Victor A Miranda, MD
Contact
vmirandah@med.puc.cl
+56988291697
Sebastian Viguera, MD
Contact
sebastian.viguera@gmail.com
+56993316816

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion